Drug Discovery World

JULY 24, 2023

Ginkgo will lead a team comprising representatives from Imperial College London, led by Professor Paul Freemont, Nature’s Toolbox, led by Alex Koglin, and consultant Michael Feldhaus (former Executive VP of Antibody Discovery at Adimab).

Protein 52

Protein Manufacturing Gene Sequencing Production 52

The Pharma Data

MARCH 24, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The Phase III D8110C00001 trial is part of this funding agreement. BARDA, ASPR, HHS. JPEO-CBRND.

Radiology 52

Radiology Vaccination Vaccine Trials 52

The Pharma Data

MARCH 22, 2021

Ann Falsey, Professor of Medicine, University of Rochester School of Medicine, US, and co-lead Principal Investigator for the trial, said: “These findings reconfirm previous results observed in AZD1222 trials across all adult populations but it’s exciting to see similar efficacy results in people over 65 for the first time. JPEO-CBRND.

Trials 52

Trials Vaccination Vaccine Radiology 52

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Dr. Bahassi explained that technological advances in genetic sequencing of cfDNA have enabled liquid biopsies and led to marked increase in the detection of therapeutically-targetable mutations.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

AUGUST 30, 2022

We know that a lot of different pathologies, especially as we’ve entered the era of molecular medicine and gene therapies, cause many of the same symptoms and work through final common pathways. Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies.

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

AUGUST 22, 2021

AZD7442 is the first antibody combination (non-vaccine) modified to potentially provide long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial. In the placebo arm, there were three cases of severe COVID-19, which included two deaths.

Trials 52

Trials Antibody Vaccination Vaccine 52

Delveinsight

DECEMBER 10, 2020

Scientists at the University of Utah School of Medicine have found a way to control that autoimmune response by aiming a protein that is vital for T-cell activation. At the same time, the other had very high levels of antibodies, which neutralise the adeno-associated virus (AAV) utilised to deliver the treatment.

Gene Therapy 52

Gene Therapy Gene Vaccination Vaccine 52